The relaxation will last for quite a few hours, its a very euphoric high with a chance for the giggles every now and then
Canadians hoping to celebrate next Canada Day with a legal joint might see their summer plans go up in smoke. Conservative senators are threatening to delay marijuana legalization in Canada until the end of 2018.
Legalization of cannabis’ medicinal use is rapidly increasing worldwide, raising the need to evaluate medical implications of cannabis. Currently, evidence supports cannabis and its active ingredients as immune-modulating agents, affecting T-cells, B-cells, monocytes, and microglia cells, causing an overall reduction in pro-inflammatory cytokine expression and an increase in anti-inflammatory cytokines. Due to the supporting evidence of cannabinoids as an immune-modulating agent, research focusing on cannabinoids and autoimmunity has emerged.
Parkinson’s disease (PD), a neurodegenerative disorder, is the second most common neurological illness in United States. Neurologically, it is characterized by the selective degeneration of a unique population of cells, the nigrostriatal dopamine neurons. The current treatment is symptomatic and mainly involves replacement of dopamine deficiency. This therapy improves only motor symptoms of Parkinson’s disease and is associated with a number of adverse effects including dyskinesia. Therefore, there is unmet need for more comprehensive approach in the management of Parkinson’s disease and neurodegenerative and movement disorders. The potential for cannabis to enhance the quality of life of Parkinson’s patients is explored.
Alongside bottles of vodka, whisky and rum, marijuana will soon be stocked on the shelves of liquor stores in Nova Scotia, Canada. The provincial government announced last week that the Nova Scotia Liquor Corporation (NSLC), the province’s sole alcohol distributor, would be responsible for selling recreational marijuana in the province once Canada legalizes weed — a…